- Home
- INO vs ADAG Comparison
INO vs ADAG Comparison
Compare INO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- ADAG
- Stock Information
- Founded
- INO 1979
- ADAG 2011
- Country
- INO United States
- ADAG China
- Employees
- INO N/A
- ADAG N/A
- Industry
- INO Medical/Dental Instruments
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- ADAG Health Care
- Exchange
- INO Nasdaq
- ADAG Nasdaq
- Market Cap
- INO 136.6M
- ADAG 110.8M
- IPO Year
- INO 1998
- ADAG 2021
- Fundamental
- Price
- INO $2.58
- ADAG $1.80
- Analyst Decision
- INO Buy
- ADAG Strong Buy
- Analyst Count
- INO 5
- ADAG 3
- Target Price
- INO $8.80
- ADAG $7.67
- AVG Volume (30 Days)
- INO 1.0M
- ADAG 77.7K
- Earning Date
- INO 11-10-2025
- ADAG 08-12-2025
- Dividend Yield
- INO N/A
- ADAG N/A
- EPS Growth
- INO N/A
- ADAG N/A
- EPS
- INO N/A
- ADAG N/A
- Revenue
- INO $182,337.00
- ADAG $103,204.00
- Revenue This Year
- INO N/A
- ADAG $7,411.34
- Revenue Next Year
- INO $14,751.49
- ADAG $28.29
- P/E Ratio
- INO N/A
- ADAG N/A
- Revenue Growth
- INO N/A
- ADAG N/A
- 52 Week Low
- INO $1.30
- ADAG $1.33
- 52 Week High
- INO $5.80
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- INO 58.30
- ADAG 43.15
- Support Level
- INO $2.21
- ADAG $1.75
- Resistance Level
- INO $2.49
- ADAG $1.95
- Average True Range (ATR)
- INO 0.14
- ADAG 0.12
- MACD
- INO -0.01
- ADAG -0.00
- Stochastic Oscillator
- INO 81.29
- ADAG 28.57
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.